About OliPass
OliPass is a company based in Yongin (South Korea) founded in 2006. OliPass operates in a competitive market with competitors including Dicerna Pharmaceuticals, Stoke Therapeutics, CureVac, Vico and Orna, among others.
- Headquarter Yongin, South Korea
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website olipass.com
- Investors
Funding Insights of OliPass
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of OliPass with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2018 | – | Seed | – | SJ Investment Partners | – |
1 investors in total: 1 institutional.
Investors in OliPass
OliPass has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include SJ Investment Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | sjinvest.co.kr | - |
Investor details for OliPass
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of OliPass
3 dated milestones of OliPass across 13 years, from founding to its latest funding, stage changes and deals.
- Founded OliPass is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
Competitors of OliPass
OliPass operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Dicerna Pharmaceuticals, Stoke Therapeutics, CureVac, Vico and Orna, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dicerna.com | 2007 | Lexington, United States | $106.45M | 337 | Drugs are developed using RNA interference technology platform. | |
| stoketherapeutics.com | 2014 | Bedford, United States | $130.85M | 117 | Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing | |
| curevac.com | 2000 | Tubingen, Germany | $975.35M | 648 | mRNA-based therapeutics against cancer and infectious diseases are developed. | |
| vicotx.com | 2019 | Leiden, Netherlands | $103.3M | – | RNA modulating therapies for genetic neurological diseases are developed. | |
| ornatx.com | 2020 | Cambridge, United States | $201M | 113 | Technologies for producing circular RNA therapeutics are developed. | |
| envisagenics.com | 2014 | Long Island, United States | $46.78M | – | RNA splicing therapeutics are discovered and developed through AI-driven biotechnology. | |
| rznomics.com | 2017 | – | $39.8M | – | Developer of drugs for anti-cancer and refractory diseases based on RNA Platform technology | |
| expansionrx.com | 2016 | San Diego, United States | $140.3M | 20 | Software for RNA-based drug development is provided by the company. | |
| renagadetx.com | 2021 | Cambridge, United States | $300M | 136 | RNA-based medicines are developed for treating multiple diseases. |
Detailed competitors of OliPass
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OliPass
The website of OliPass (olipass.com) receives about 7.6K visits a month and ranks #3,376,829 among all websites worldwide, #4,419 in Biotechnology and Pharmaceuticals.
- Monthly visits7.6K
▲ 40% vs previous month
- Unique visitors2.4K
per month
- Global rank#3,376,829
among all websites
- Category rank#4,419
Health · Biotechnology and Pharmaceuticals
- Bounce rate31%
- Pages per visit1.9
- Average visit15 sec
- DevicesDesktop 12% · Mobile 88%
Websites whose visitors overlap most with OliPass. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hitnews.co.kr | 100% | – | #146,502 | View details |
Latest news on Olipass
Complete news archive for OliPass
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to OliPass
10 companies that operate in the same segment as OliPass (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OliPass
OliPass was founded in 2006 and raised its 1st funding round 12 years after it was founded.
OliPass is headquartered in Yongin, South Korea. It is registered at Yongin, Gyeonggi, South Korea.
OliPass is a company with limited information available on its website. The specific nature of its business activities, sectors, or solutions is not disclosed in the provided content. Further details regarding its operations or offerings are not accessible at this time.
OliPass's top competitors include Dicerna Pharmaceuticals, Orna and Vico.
OliPass has 1 investor. Key investors include SJ Investment Partners.